Iterum Therapeutics Provides Business Update

(NASDAQ:ITRM), DUBLIN and CHICAGO, Dec. 05, 2025 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update. Recent Events Market Access […]

Holzer & Holzer, LLC Reminds Investors of Upcoming December 8, 2025 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Marex, Inc. (MRX), aTyr Pharma, Inc. (ATYR), WPP plc (WPP) , and Cepton, Inc. (CPTN)

(NASDAQ:ATYR),(NASDAQ:MRX),(NYSE:WPP),(NASDAQ:CPTN), ATLANTA, Dec. 05, 2025 (GLOBE NEWSWIRE) — Holzer & Holzer, LLC reminds investors of the deadline to seek to be appointed lead plaintiff in the following class action lawsuits: Marex, Inc. (MRX) The shareholder class action lawsuit filed against Marex, Inc. (“Marex” or the “Company”) (NASDAQ: MRX) alleges that Defendants made materially false and/or

AI Back-End Networks Continue Their Shift to Ethernet, Now Accounting for Over Two-Thirds of 3Q 2025 Switch Sales in AI Clusters, According to Dell’Oro Group

Accton, Arista, and Cisco Gained the Most Share, While Celestica and NVIDIA Continue toLead with Nearly 50 Percent Combined Share in the Ethernet Segment According to a recently published report from Dell'Oro Group, the trusted source for market information about the telecommunications, security, networks, and data center industries, Ethernet accounted for more than two-thirds of

K36 Therapeutics announces presentation of First-in-Human Clinical Data for Gintemetostat (KTX-1001) Demonstrating Target Engagement and Clinical Activity in Multiple Myeloma at ASH 2025 and the Appointment of Dr. Shinta Cheng, M.D., Ph.D., as Chief Medical Officer

First-in-human data highlights safety, pharmacodynamics, and single-agent activity supporting MMSET/NSD2 inhibition in heavily pre-treated multiple myeloma patients Shinta Cheng, M.D., Ph.D., joins K36 to drive clinical development of lead programs and oncology pipeline expansion K36 Therapeutics, Inc.(“K36”), a clinical-stage biotechnology company developing first-in-class MMSET/NSD2 inhibitors for genetically defined cancers, today announced that clinical data from

Olympus, Gore, and ConMed Announce Transition of Commercial Support for the GORE® VIABIL® Biliary Endoprosthesis in the United States

Olympus Corporation (“Olympus”), W. L. Gore & Associates, Inc. (“Gore”), and ConMed Corporation (“ConMed”) jointly announced today the upcoming transition of commercial support and distribution for the GORE® VIABIL® Biliary Endoprosthesis for endoscopic placement (“VIABIL® device”) in the United States. This announcement follows the signed agreement between Gore and Olympus by which the exclusive global

Trumid Reports Record RFQ Volume in November

32% YoY platform growth driven by record client engagement in list-based protocols Trumid, a financial technology company and leading fixed income electronic trading platform, today announced trade volume and user participation highlights for November 2025. https://mma.prnewswire.com/media/2544830/Trumid_Logo.jpg High Yield ADV rose 38% year-over-year, supported by elevated Trumid PT and Trumid Swarms activity November Highlights: Trumid sustained

Blueprint Medicines, a Sanofi Company, Highlights Long-Term Clinical Benefit of AYVAKIT® (avapritinib) Across Indolent and Advanced Systemic Mastocytosis at 2025 ASH Annual Meeting

Durable disease control and quality-of-life improvements for patients with ISM in the PIONEER trial — Prolonged survival, including in the first-line treatment setting, for patients with advanced SM in the PATHFINDER trial — Blueprint Medicines, aSanofi company, today announced updated data reinforcing the clinical efficacy and safety of long-term AYVAKIT®(avapritinib) use across the spectrum of

Jubilant Therapeutics Inc. appoints Daniel J. O’Connor as President and Chief Executive Officer

Jubilant Therapeutics Inc., a clinical-stage biopharmaceutical company developing novel small molecule modulators for oncology and autoimmune diseases, today announced the appointment of Daniel J. O'Connor as President & Chief Executive Officer, effective December 1, 2025. https://mma.prnewswire.com/media/2839402/Daniel_J_O_Connor_Jubilant.jpg Dan brings more than 30 years of leadership experience in biotechnology and oncology, with a proven track-record of creating

Trigent Partners with WeWork India to Expand its GCC Footprint

Strategic collaboration accelerates intelligence-driven Global Capability Centers bringing enterprise-grade processes, startup agility, and flexible workspaces Trigent, a leading technology solutions provider with over 30 years of engineering and custom software solution excellence, has entered into a strategic partnership with WeWork India, one of India's leading premium flexible workspace providers. The collaboration further strengthens Trigent's Global

New Article Highlighting Leading Wine and Beverage Brands in California Published by Digital Silk

A new article examining standout wine and beverage brands across the state has been released byDigital Silk, an award-winning digital agency focused on creating brand strategies, custom websites and digital marketing campaigns. The resource provides an overview of notable producers shaping California's wine and beverage landscape, referencing publicly available industry information and regional market activity.

Scroll to Top